Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Receivables - Other (2020 - 2025)

Historic Receivables - Other for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $1.7 million.

  • Tarsus Pharmaceuticals' Receivables - Other rose 4986.9% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 4986.9%. This contributed to the annual value of $1.3 million for FY2024, which is 1884.72% up from last year.
  • According to the latest figures from Q3 2025, Tarsus Pharmaceuticals' Receivables - Other is $1.7 million, which was up 4986.9% from $1.9 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' Receivables - Other's 5-year high stood at $7.2 million during Q1 2021, with a 5-year trough of $139000.0 in Q3 2021.
  • In the last 5 years, Tarsus Pharmaceuticals' Receivables - Other had a median value of $1.1 million in 2024 and averaged $1.6 million.
  • Per our database at Business Quant, Tarsus Pharmaceuticals' Receivables - Other soared by 1380000.0% in 2021 and then crashed by 9574.94% in 2022.
  • Over the past 5 years, Tarsus Pharmaceuticals' Receivables - Other (Quarter) stood at $200000.0 in 2021, then soared by 1691.0% to $3.6 million in 2022, then crashed by 69.49% to $1.1 million in 2023, then grew by 18.85% to $1.3 million in 2024, then soared by 32.1% to $1.7 million in 2025.
  • Its Receivables - Other stands at $1.7 million for Q3 2025, versus $1.9 million for Q2 2025 and $1.7 million for Q1 2025.